Drugs / TAK-411
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06798012 | May 2025 → Dec 2027 expected | chronic inflammatory demyelinating polyradiculoneuropathy | Takeda | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-411 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06798012 ↗ |
| Modality | Protein / enzyme biologic | “TAK-411 is a special type of immune globulin G (hsIgG) that has been chemically changed.” NCT06798012 ↗ |
| Route | Intravenous | “TAK-411 IV infusion.” NCT06798012 ↗ |